Compare KLA Corp. (KLAC) vs TG Therapeutics Inc (TGTX) Price & Performance

KLA Corporation (KLAC) trades at $212.75, down 3.02% amid a semiconductor sector correction. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $0.94 and robust profitability metrics including a 35.66% net income margin. Technical indicators signal bearish momentum with support at $210 and resistance at $222. Recent corporate actions include a 1:10 stock split effective June 12, 2026, and a $2.30 dividend paid in June 2026.

KLAC's dominant position in semiconductor process control and AI-driven equipment demand support long-term growth, but rich valuation multiples (P/E 60.25, P/S 21.48) and sector volatility pose near-term risks. Analyst consensus remains bullish with a $243.43 price target (14% upside), though technical breakdowns suggest potential further downside to $203 support.

TG Therapeutics (TGTX) trades at $54.84, down 0.16% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with 65.95% net income margin and 112.6% ROE, though valuation metrics appear elevated with P/E of 19.18 and P/S of 12.59. Recent positive Phase 1 data for subcutaneous Briumvi in myasthenia gravis and initiation of Phase 2 trials in schizophrenia provide clinical catalysts. Earnings have been mixed with a Q3 2025 beat but subsequent misses, while cash flow turned positive in 2026 projections.

The outlook remains positive with 84.6% analyst buy ratings and $48.50 consensus target, though current price exceeds this. Key opportunities include Briumvi's expanding indications and strong revenue growth to $700M projected for 2026. Risks include ongoing shareholder litigation investigation, clinical trial execution, and high valuation multiples requiring sustained growth. The stock faces resistance near $56 with support at $54.